For decades, research into compounds such as psilocybin, LSD and MDMA was effectively frozen. A small number of determined advocates kept the scientific case alive at a time when doing so could come at a cost to their careers. Few did more than Lady Amanda Feilding, whose insistence on rigorous, collaborative science helped bring psychedelics back into respected universities and, ultimately, into the drug development pipeline. Her approach was simple and radical: let the evidence speak.

Today, the evidence is speaking. Psychedelic and psychedelic-inspired therapies are in late-stage clinical trials for depression, PTSD, anxiety and addiction. Regulators have engaged seriously, investors have committed significant capital, and established pharmaceutical companies are watching closely. The question is no longer whether these treatments can work, but who will lead the organisations bringing them to patients.

Leadership Is Now the Bottleneck

The science has matured faster than the talent pool around it. Psychedelic medicine is a young field, and the number of executives who have taken a psychedelic programme through late-stage trials is still very small.

That creates a genuine challenge. These companies are not conventional neuroscience businesses. They must design trials where blinding is difficult, build therapy models that combine a drug with structured psychological support, and work with regulators who are writing the rulebook in real time. They must also manage public perception in a field that still carries decades of stigma.

Getting leadership right is therefore not a secondary concern. In a sector where a single trial readout or regulatory decision can define a company's future, the quality of the executive team and board is often the deciding factor.

What We Have Learned From Working Across the Sector

At The RSA Group, we have recruited for some of the most prominent names in psychedelic medicine, from early pioneers to companies now running late-stage programmes. Our work has spanned the wider landscape too, from the medical cannabis sector to established neuroscience companies with deep CNS pipelines.

That breadth has taught us a few things:

• The best candidates rarely come from inside the sector. The talent pool is too small. Most strong hires bring proven experience from psychiatry, CNS drug development or regulated consumer health, combined with a genuine openness to a new therapeutic model.

• Conviction matters, but so does scepticism. Boards want leaders who believe in the potential of these therapies, but who also hold that belief to a rigorous scientific standard. Unbridled enthusiasm without careful reflection on risk is a warning sign.

• Established neuroscience companies are a vital talent source. Executives who have built and commercialised CNS products bring the regulatory and commercial experience that younger psychedelic companies often lack.

• The sector has already been through cycles. We have seen boom, correction and consolidation. Leaders who have navigated a downturn and kept a programme funded are especially valuable.

The Profile of a Psychedelic Medicine Leader

No single CV fits every role, but the strongest leaders we have placed tend to share five qualities:

1. Clinical and regulatory fluency. They understand psychiatric trial design and can engage credibly with regulators on novel questions such as functional unblinding and therapist-assisted dosing.

2. Comfort with complexity. Many therapies involve a drug, a trained therapist and a care setting. Leaders must think about the whole treatment model, not just the molecule.

3. Commercial imagination. Reimbursement, clinic capacity and therapist training are unsolved problems. The right leader sees these as design challenges, not afterthoughts.

4. Credibility with investors. The sector depends on patient capital. Leaders must explain long timelines and binary risks with clarity and honesty.

5. Ethical seriousness. Patient safety, informed consent and responsible communication carry extra weight in a field still earning public trust.

Advice for Boards and Investors

For those building or backing psychedelic medicine companies, a few principles have served our clients well:

• Hire for the next stage, not the current one. A founding team that excelled in discovery may not be the team to run a pivotal trial or launch a product. Plan leadership transitions early.

• Look beyond the obvious pool. Search widely across psychiatry, CNS and adjacent regulated sectors. Some of the best candidates have never worked with a psychedelic compound.

• Strengthen the board alongside the executive team. Non-executives with regulatory, payer or commercial launch experience can give a young company the credibility it needs.

• Test for values as well as experience. Ask candidates how they would handle a disappointing readout or a safety signal. Their answers reveal more than their CVs.

Finishing What the Pioneers Started

Amanda Feilding and her contemporaries have laid the groundwork and broken down the hardest barriers. The next chapter belongs to the executives, clinicians and board members who can turn promising data into approved, accessible treatments.

That will take leaders who combine scientific rigour with the courage to work in uncharted territory. Finding them is one of the most important and rewarding challenges in life sciences today, and one we are proud to be part of.

Ollie Stephens, The RSA Group.

To discuss leadership in psychedelic medicine or CNS, get in touch at www.theRSAgroup.com.